The FDA approves Eli Lilly’s (LLY) Cyramza (ramucirumab) for advanced stomach cancer and gastroesophogeal junction adenocarcinoma. The product is an angiogenesis inhibitor that blocks the blood supply to tumors.
According to the National Cancer Institute over 22K people will be diagnosed with stomach cancer this year. The mortality rate is ~50%.
var isMC=true; var adSize=’320×50′; var ord = Math.floor(Math.random()*10e12); var seekingalpha_ad_src=’http://ad.doubleclick.net/N6001/adj/sek.mobile/app;sz=320×50,320×250;x=x;tile=1;d=mobile;t=app;mcid=true;mcid=1683633;s=LLY;’+dart_my_vocation_and_profiles()+’ord=’+ord+’;dev=ip?’; document.write(”);
April 22nd, 2014 at 6:56 am
FDA green lights Lilly cancer drug
Yesterday, 05:16 PM ET · LLY